Immatics N.V. filings document a foreign private issuer whose regulatory record centers on clinical-stage oncology development, financing capacity and public-company governance. Form 6-K reports furnish press releases, interim reports and investor presentations covering PRAME cell therapy and TCR bispecific programs, including anzu-cel, IMA203CD8, IMA402 and IMA401 MAGEA4/8, along with financial results and business updates.
The filings also include incorporation-by-reference language for Form S-8 and Form F-3 registration statements, leadership and governance disclosures, forward-looking clinical and regulatory risk statements, and capital-structure or shareholder matters tied to the company's Nasdaq-traded security.
Immatics N.V. reported a wider net loss of €57.8 million for the three months ended March 31, 2026, compared with €39.9 million a year earlier, or €0.43 loss per share. Revenue from collaboration agreements declined to €7.6 million from €18.6 million, mainly due to lower cost-based progress on the Moderna and BMS partnerships. Research and development expenses rose to €59.2 million, driven by increased spending on PRAME-focused TCR cell therapies and bispecifics, particularly the SUPRAME Phase 3 trial for anzu-cel. Immatics ended the quarter with cash, cash equivalents and other financial assets totaling €453.6 million ($521.5 million), and projects its cash reach into 2028 while advancing multiple PRAME-targeted clinical programs and preparing for a potential first commercial launch of anzu-cel in 2027.
Immatics N.V. filed a report noting that all of its submitted scientific abstracts were selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The Company will deliver four talks covering both its PRAME-directed T-cell therapies and its T-cell receptor-based bispecifics.
Presentations will highlight patient-level response data in advanced melanoma for anzutresgene autoleucel (anzu-cel), Phase 1 results for IMA203CD8 in ovarian cancer, Phase 1 PRAME T-cell therapy data in synovial sarcoma, and first-in-human results for the MAGEA4/8 bispecific IMA401 in recurrent or refractory solid tumors. Immatics positions itself as a global leader in precision targeting of PRAME across multiple cancer indications.
Immatics N.V. reports that an abstract describing a pediatric case treated with its PRAME-directed TCR cell therapy has been accepted as a late-breaking poster at the AACR Annual Meeting 2026 in San Diego.
The case involves a 17-year-old with PRAME-positive advanced metastatic nephroblastoma who had exhausted standard treatment options. After receiving a TCR T-cell therapy using Immatics’ PRAME TCR encoded by the IMA203CD8 lentiviral vector, the patient achieved deep anti-tumor remission, first seen three months after infusion and ongoing at six months of follow-up. Imaging showed marked regression across lung, liver, brain and abdominal lesions, and liquid biopsy no longer detected tumor-derived DNA, indicating molecular remission. Cytokine release syndrome occurred but was described as manageable and resolved with multi-modal anti-cytokine therapy and corticosteroids. Immatics highlights PRAME as a target expressed in more than 50 cancers and plans to evaluate its PRAME TCR T-cell therapies in pediatric patients, including assessing a potential first-in-pediatrics Phase 1/2 basket study for relapsed or refractory PRAME-expressing solid tumors at KiTZ in Heidelberg.
Immatics N.V. Chief Development Officer Carsten Alexander Johannes Reinhardt filed a Form 3 reporting his initial ownership in the company. He holds 47,781 Ordinary Shares directly, a series of stock options to buy additional Ordinary Shares at exercise prices ranging from $1.06 to $11.00 with expirations between 2027 and 2036, and 40,000 restricted stock units that vest in four equal annual installments beginning on January 8, 2026.
Immatics N.V. Chief Medical Officer Cedrik Michael Britten has filed an initial Form 3 detailing his equity holdings in the company. The filing lists multiple stock options to buy Ordinary Shares at exercise prices between $8.0600 and $11.0000, with expirations ranging from 2030-06-01 to 2036-01-07. Individual grants include, for example, options over 255,000 underlying Ordinary Shares at an exercise price of $10.0000 expiring on 2030-06-30, and options over 200,000 underlying Ordinary Shares at an exercise price of $9.3200 expiring on 2036-01-07. Footnotes describe vesting schedules, including options that are fully vested and others that vest over four-year periods. The filing also reports 50,000 restricted stock units, each convertible into one Ordinary Share, and 250 Ordinary Shares held directly. This Form 3 records existing positions and does not show any new purchases or sales.
Immatics N.V. filed an initial Form 3 for General Counsel Edward A. Sturchio Jr., detailing his equity-based holdings. The filing lists multiple stock options to buy Ordinary Shares with exercise prices ranging from $8.06 to $12.92 and expirations between 2030 and 2036. It also discloses restricted stock units covering 40,000 Ordinary Shares, which vest in four equal annual installments starting on January 8, 2026. Some options are already fully vested, while others vest over time based on market capitalization performance hurdles and service-based schedules.
Immatics N.V. executive Jordan Zeik Silverstein, Head of Strategy, reported his beneficial holdings of the company’s securities. The filing lists multiple stock option awards over Ordinary Shares at exercise prices ranging from $1.1700 to $11.0000, with expirations from 2028 through 2036, alongside 50,000 restricted stock units and 7,826 Ordinary Shares held directly. Footnotes explain that one option grant is fully vested and others, as well as the RSUs, vest in scheduled installments over several years.
Immatics N.V. director and Chief Executive Officer Harpreet Singh Jasuja filed an initial ownership report showing a mix of ordinary shares, stock options and restricted stock units. He directly holds 217,241 ordinary shares and multiple option grants over ordinary shares with exercise prices ranging from $1.06 to $11.00, plus 167,500 RSUs that each convert into one ordinary share as they vest over time.
Immatics N.V. director Alise Reicin reported existing holdings of stock options in the company. The filing shows options to buy 60,000 ordinary shares at an exercise price of $12.08 per share, expiring on July 28, 2034, vesting in 12 equal quarterly installments over 36 months from the grant date of July 29, 2024. It also lists options to buy 41,500 ordinary shares at an exercise price of $5.44 per share, expiring on June 23, 2035, which vest 100% on the first anniversary of the grant date, June 24, 2025. These entries describe current derivative holdings rather than new open‑market purchases or sales.
Immatics N.V. reported the initial beneficial ownership of its Chief Financial Officer, Ramanan Venkat, in a Form 3. He holds a stock option to buy 350,000 ordinary shares at an exercise price of $9.0000 per share, expiring on September 30, 2035.
These options vest 25% on the first anniversary of the grant date, October 1, 2025, with the remaining 75% vesting in 12 equal quarterly installments over the following three years. The filing shows this option position as a direct holding and does not report any open-market buying or selling activity.